Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity

Dendritic cell (DC)-based immunotherapy is explored worldwide in cancer patients, predominantly with DC matured with pro-inflammatory cytokines and prostaglandin E(2). We studied the safety and efficacy of vaccination with monocyte-derived DC matured with a cocktail of prophylactic vaccines that con...

Descripción completa

Detalles Bibliográficos
Autores principales: Bol, Kalijn F., Aarntzen, Erik H. J. G., Pots, Jeanette M., Olde Nordkamp, Michel A. M., van de Rakt, Mandy W. M. M., Scharenborg, Nicole M., de Boer, Annemiek J., van Oorschot, Tom G. M., Croockewit, Sandra A. J., Blokx, Willeke A. M., Oyen, Wim J. G., Boerman, Otto C., Mus, Roel D. M., van Rossum, Michelle M., van der Graaf, Chantal A. A., Punt, Cornelis J. A., Adema, Gosse J., Figdor, Carl G., de Vries, I. Jolanda M., Schreibelt, Gerty
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779136/
https://www.ncbi.nlm.nih.gov/pubmed/26861670
http://dx.doi.org/10.1007/s00262-016-1796-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4779136/
https://www.ncbi.nlm.nih.gov/pubmed/26861670
http://dx.doi.org/10.1007/s00262-016-1796-7

Ejemplares similares